Virpax Pharmaceuticals, Inc. (VRPX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol VRPX
- Company Virpax Pharmaceuticals, Inc.
- Price $0.25
- Changes Percentage 19.05
- Change 0.04
- Day Low $0.25
- Day High $0.31
- Year High $91.18
- Year Low $0.14
- Market Cap $310,625
- Price Avg 50 EMA (D) $3.7
- Price Avg 200 EMA (D) $14
- Exchange NASDAQ
- Volume 11,584
- Average Volume 402,685
- Open $0.27
- Previous Close $0.21
- EPS -71
- PE 0.00
- Earnings Announcement 2025-05-12 04:00:00
- Shares Outstanding $1,242,500
Company brief: VIRPAX PHARMACEUTICALS, INC. (VRPX )
- Healthcare
- Biotechnology
- Mr. Gerald W. Bruce
- https://www.virpaxpharma.com
- US
- N/A
- 02-17-2021
- US9282511073
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.